SCYNEXIS Provides Corporate, Commercial and R&D Strategy Updates to Expand Market Potential for Its First-in-Class Antifungal

20.10.2022 - SCYNEXIS is announcing a new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications in which higher long-term returns are expected, given the promising data generated to date ... Seite 1

Related Keywords

Jersey ,Christine Coyne ,Marco Taglietti ,David Angulo ,Ivor Macleod ,Globe Newswire Scynexis Inc ,Amplity Health ,Nasdaq ,Chief Executive Officer ,Chief Medical Officer ,Chief Financial Officer ,Chief Commercial Officer ,